Pro Medicus has secured a new $128 million contract with NYC Health + Hospitals
(Image source: Canva)
Get your Free Report on Top 5 ASX stocks for 2025
Pro Medicus Limited (ASX: PME) announced on 20 November 2026 that its wholly owned US subsidiary, Visage Imaging, Inc., had signed a 10-year contract worth $128 million with NYC Health + Hospitals.
The company will provide its complete Visage 7 Enterprise Imaging Platform across the healthcare organisation under the agreement.
The contract covers three products, namely Visage 7 Viewer, Visage 7 Workflow and Visage 7 Open Archive, which together form a unified diagnostic imaging platform.
NYC Health + Hospitals will implement the Visage 7 platform in the cloud to modernise its existing medical imaging infrastructure.
As part of the deal, Visage will also migrate the organisation's legacy PACS archives to its Visage 7 Open Archive solution.
The platform will support the distribution of medical images across the organisation through its integration with NYC Health + Hospitals' electronic health record system.
Pro Medicus has adopted a transaction-based licensing model for this contract. The company will begin planning for the rollout immediately and will use Visage's established cloud-based implementation process.
Pro Medicus has set a target to bring the platform into operation in late Q3 of calendar year 2027.
(Source:- Company Announcements)
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
Feature News
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialRecent News
88 Energy is set to expand Kad River East Project ..
Genetic Signatures has ended proposed merger with ..
Perenti Secures A$1 Billion Five-Year Underground ..
ClearVue secures award for a public project in Sin..
Omega Oil & Gas Records Queensland’s Deepest Wel..